The Cardiac Amyloidosis Market focuses on novel therapies designed to treat amyloid protein deposition in cardiac tissue, aiming to improve patient survival and quality of life. Leading products include transthyretin stabilizers such as tafamidis, gene-silencing agents like patisiran and inotersen, and emerging monoclonal antibodies targeting misfolded proteins. These pharmaceuticals offer advantages such as targeted mechanism of action, reduced hospitalization rates, and fewer adverse events compared to traditional heart failure treatments. Cardiac Amyloidosis Market Growing awareness of non‐invasive diagnostic tools—echocardiography, cardiac MRI and scintigraphy—underscores the need for early intervention. As healthcare providers seek to address market challenges like late-stage diagnosis and limited treatment options, ongoing clinical research and collaboration among market players have become vital. Continued investment in product development and regulatory approvals is creating significant market opportunities, while evolving market trends hint at expansion of reimbursement frameworks and enhanced patient access programs. Global prevalence of cardiac amyloidosis, driven by an aging population and improved disease recognition, will sustain market growth.
The Global Cardiac Amyloidosis Market is estimated to be valued at USD 6.51 Bn in 2025 and is expected to reach USD 10.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.
Key Takeaways
Key players operating in the Cardiac Amyloidosis Market are Pfizer, Alnylam Pharmaceuticals, Alexion Pharmaceuticals/Eidos Therapeutics, Ionis Pharmaceuticals, and AstraZeneca. These market companies lead in R&D investment, leveraging advanced clinical trials and strategic partnerships to strengthen their market share. Pfizer’s global reach and AstraZeneca’s development of next-generation therapeutics illustrate robust market growth strategies. Alnylam Pharmaceuticals and Ionis Pharmaceuticals focus on RNA‐based approaches, reflecting the expanding scope of innovative therapies. Alexion’s collaboration with Eidos Therapeutics highlights a dynamic pipeline, supported by comprehensive market research that informs portfolio decisions and competitive positioning.
Cardiac Amyloidosis Market
https://www.coherentmi.com/industry-reports/cardiac-amyloidosis-market
Top comments (0)